3 completed. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 2 |
Follow PER977: new trials by email Literature Review of PER977 trials Research Report on PER977
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin PER977, Placebo, Heparin Sodium - Healthy | Phase 1 / Phase 2 | Completed | Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. | 60 | 2014-06-01 | 2020-05-21 |
| PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin PER977, Placebo, enoxaparin - Healthy | Phase 1 / Phase 2 | Completed | Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. | 40 | 2014-04-01 | 2020-05-21 |
| Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban PER977, Placebo - Anticoagulant Reversal, Reversal of Edoxaban Induced Anticoagulation | Phase 1 | Completed | Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. | 83 | 2013-07-01 | 2020-05-28 |
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. (3)
United States (3)
Barbara Lomeli, MD (1) · Robert Noveck, MD, PhD (1) · Scott Rasmussen, MD (1)